Paper Details

  1. Home
  2. Paper Details

Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid.

Author: BlancoA, BrentaG, DamilanoS, FaccoE, FretesO, GonzalezE, GurfinkelM, PacenzaN, PisarevM A, SchnitmanM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Triiodothyroacetic acid (TRIAC) is more effective than levothyroxine (L-T4) in reducing goiter size in euthyroid women, with comparable effects on peripheral parameters.
Paper Details　
Original Abstract of the Article :
Euthyroid goiter is usually treated with TSH-inhibitory doses of levo-T(4) (L-T(4)). Because triiodothyroacetic acid (TRIAC) decreases TSH levels, the following study was perfomed: 36 euthyroid goitrous female patients (no cancer or chronic thyroiditis) were randomized to TRIAC (19.6 micro g/kg) (n ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1210/jc.2003-030095

データ提供：米国国立医学図書館（NLM）

Treating Euthyroid Goiter: Finding the Right Path in the Thyroid Desert

The [thyroid gland] can be a challenging terrain, especially when it comes to treating [euthyroid goiter]. This study delves into the complexities of managing this condition, comparing two common treatments: [levo-thyroxine (L-T(4))] and [triiodothyroacetic acid (TRIAC)]. The researchers conducted a [randomized study] involving 36 female patients with euthyroid goiter. They measured various parameters like [goiter volume, bone mineral density, and serum markers] before and after treatment. The results revealed that [TRIAC was more effective] in reducing goiter size compared to L-T(4), with comparable effects on other parameters.

A More Effective Oasis: TRIAC

[TRIAC] emerged as the more effective treatment for reducing goiter size, with [a significant difference] observed compared to L-T(4). This finding suggests that [TRIAC could be a valuable option] for patients seeking goiter reduction. The study also indicated that [TRIAC was associated with fewer side effects] than L-T(4). This discovery is like finding a hidden oasis in the desert of thyroid treatment options, offering a more comfortable and potentially more effective path.

Navigating Thyroid Health with Informed Choices

While [TRIAC] shows promising results, it's important to remember that [individual needs and preferences] should always be considered. Consulting with your doctor and discussing treatment options is crucial for making informed decisions about your thyroid health. Just like navigating a desert, it's essential to seek guidance and find the path that best suits your needs and leads to a healthier, more comfortable journey.

Dr. Camel's Conclusion

This research offers valuable insights into the treatment of euthyroid goiter, highlighting the potential benefits of TRIAC. The study suggests that TRIAC could be a more effective and well-tolerated option for reducing goiter size compared to L-T(4). It emphasizes the importance of individualizing treatment plans based on patient needs and preferences, ensuring a personalized approach to navigating thyroid health.

Date :
  1. Date Completed 2003-12-09
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

14602763

DOI: Digital Object Identifier

10.1210/jc.2003-030095

Related Literature

Article Analysis
・Side Effects of levothyroxine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.